Aprocitentan: Dual endothelin eta/etb receptor antagonist treatment of resistant hypertension

Authors
Category Systematic review
JournalDrugs of the Future
Year 2021
This article has no abstract
Epistemonikos ID: b2e7c1a3ea75d8d28b306b08056a2d7728afc482
First added on: Feb 13, 2025